135 related articles for article (PubMed ID: 16209341)
21. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
Malaguarnera R; Vella V; Pandini G; Sanfilippo M; Pezzino V; Vigneri R; Frasca F
Mol Cancer Res; 2008 Jan; 6(1):64-77. PubMed ID: 18234963
[TBL] [Abstract][Full Text] [Related]
22. The potential tumor suppressor p73 differentially regulates cellular p53 target genes.
Zhu J; Jiang J; Zhou W; Chen X
Cancer Res; 1998 Nov; 58(22):5061-5. PubMed ID: 9823311
[TBL] [Abstract][Full Text] [Related]
23. Targeting of p53 and its homolog p73 by protoporphyrin IX.
Sznarkowska A; Maleńczyk K; Kadziński L; Bielawski KP; Banecki B; Zawacka-Pankau J
FEBS Lett; 2011 Jan; 585(1):255-60. PubMed ID: 21146529
[TBL] [Abstract][Full Text] [Related]
24. MDM2 and MDMX can interact differently with ARF and members of the p53 family.
Wang X; Arooz T; Siu WY; Chiu CH; Lau A; Yamashita K; Poon RY
FEBS Lett; 2001 Feb; 490(3):202-8. PubMed ID: 11223036
[TBL] [Abstract][Full Text] [Related]
25. Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo.
Xirodimas D; Saville MK; Edling C; Lane DP; Laín S
Oncogene; 2001 Aug; 20(36):4972-83. PubMed ID: 11526482
[TBL] [Abstract][Full Text] [Related]
26. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.
Ichimura K; Bolin MB; Goike HM; Schmidt EE; Moshref A; Collins VP
Cancer Res; 2000 Jan; 60(2):417-24. PubMed ID: 10667596
[TBL] [Abstract][Full Text] [Related]
27. Survivin regulates the p53 tumor suppressor gene family.
Wang Z; Fukuda S; Pelus LM
Oncogene; 2004 Oct; 23(49):8146-53. PubMed ID: 15361831
[TBL] [Abstract][Full Text] [Related]
28. Identification of p53 sequence elements that are required for MDM2-mediated nuclear export.
Gu J; Nie L; Wiederschain D; Yuan ZM
Mol Cell Biol; 2001 Dec; 21(24):8533-46. PubMed ID: 11713288
[TBL] [Abstract][Full Text] [Related]
29. ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway.
Brady SN; Yu Y; Maggi LB; Weber JD
Mol Cell Biol; 2004 Nov; 24(21):9327-38. PubMed ID: 15485902
[TBL] [Abstract][Full Text] [Related]
30. MDM2 promotes the proteasomal degradation of p73 through the interaction with Itch in HeLa cells.
Kubo N; Okoshi R; Nakashima K; Shimozato O; Nakagawara A; Ozaki T
Biochem Biophys Res Commun; 2010 Dec; 403(3-4):405-11. PubMed ID: 21093410
[TBL] [Abstract][Full Text] [Related]
31. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
[TBL] [Abstract][Full Text] [Related]
32. Modulation of p53 and p73 levels by cyclin G: implication of a negative feedback regulation.
Ohtsuka T; Ryu H; Minamishima YA; Ryo A; Lee SW
Oncogene; 2003 Mar; 22(11):1678-87. PubMed ID: 12642871
[TBL] [Abstract][Full Text] [Related]
33. Syntaxin 6, a regulator of the protein trafficking machinery and a target of the p53 family, is required for cell adhesion and survival.
Zhang Y; Shu L; Chen X
J Biol Chem; 2008 Nov; 283(45):30689-98. PubMed ID: 18779328
[TBL] [Abstract][Full Text] [Related]
34. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
[TBL] [Abstract][Full Text] [Related]
35. Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination.
Chi XZ; Kim J; Lee YH; Lee JW; Lee KS; Wee H; Kim WJ; Park WY; Oh BC; Stein GS; Ito Y; van Wijnen AJ; Bae SC
Cancer Res; 2009 Oct; 69(20):8111-9. PubMed ID: 19808967
[TBL] [Abstract][Full Text] [Related]
36. p53 and Mdm2: an auld alliance.
Vigneron A; Vousden KH
Cell Cycle; 2010 Mar; 9(5):865-6. PubMed ID: 20348845
[No Abstract] [Full Text] [Related]
37. MDM2's dual mRNA binding domains co-ordinate its oncogenic and tumour suppressor activities.
Gnanasundram SV; Malbert-Colas L; Chen S; Fusée L; Daskalogianni C; Muller P; Salomao N; Fåhraeus R
Nucleic Acids Res; 2020 Jul; 48(12):6775-6787. PubMed ID: 32453417
[TBL] [Abstract][Full Text] [Related]
38. Identification of three functions of the adenovirus e4orf6 protein that mediate p53 degradation by the E4orf6-E1B55K complex.
Querido E; Morrison MR; Chu-Pham-Dang H; Thirlwell SW; Boivin D; Branton PE
J Virol; 2001 Jan; 75(2):699-709. PubMed ID: 11134283
[TBL] [Abstract][Full Text] [Related]
39. Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma.
Nicholson SA; Okby NT; Khan MA; Welsh JA; McMenamin MG; Travis WD; Jett JR; Tazelaar HD; Trastek V; Pairolero PC; Corn PG; Herman JG; Liotta LA; Caporaso NE; Harris CC
Cancer Res; 2001 Jul; 61(14):5636-43. PubMed ID: 11454718
[TBL] [Abstract][Full Text] [Related]
40. Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation.
Uchida C; Miwa S; Kitagawa K; Hattori T; Isobe T; Otani S; Oda T; Sugimura H; Kamijo T; Ookawa K; Yasuda H; Kitagawa M
EMBO J; 2005 Jan; 24(1):160-9. PubMed ID: 15577944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
